Your browser doesn't support javascript.
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.
Zuo, Jianmin; Dowell, Alexander C; Pearce, Hayden; Verma, Kriti; Long, Heather M; Begum, Jusnara; Aiano, Felicity; Amin-Chowdhury, Zahin; Hoschler, Katja; Brooks, Tim; Taylor, Stephen; Hewson, Jacqueline; Hallis, Bassam; Stapley, Lorrain; Borrow, Ray; Linley, Ezra; Ahmad, Shazaad; Parker, Ben; Horsley, Alex; Amirthalingam, Gayatri; Brown, Kevin; Ramsay, Mary E; Ladhani, Shamez; Moss, Paul.
  • Zuo J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Dowell AC; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Pearce H; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Verma K; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Long HM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Begum J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Aiano F; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Amin-Chowdhury Z; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Hoschler K; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Brooks T; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Taylor S; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Hewson J; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Hallis B; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Stapley L; Immunoassay Laboratory, National Infection Service, Porton Down, UK.
  • Borrow R; Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
  • Linley E; Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.
  • Ahmad S; Department of Virology, Manchester Medical Microbiology Partnership, Manchester Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK.
  • Parker B; The NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK.
  • Horsley A; Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  • Amirthalingam G; The NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK.
  • Brown K; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
  • Ramsay ME; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Ladhani S; Immunisation and Countermeasures Division, National Infection Service, London, UK.
  • Moss P; Immunisation and Countermeasures Division, National Infection Service, London, UK.
Nat Immunol ; 22(5): 620-626, 2021 05.
Article in English | MEDLINE | ID: covidwho-1387432
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The immune response to SARS-CoV-2 is critical in controlling disease, but there is concern that waning immunity may predispose to reinfection. We analyzed the magnitude and phenotype of the SARS-CoV-2-specific T cell response in 100 donors at 6 months following infection. T cell responses were present by ELISPOT and/or intracellular cytokine staining analysis in all donors and characterized by predominant CD4+ T cell responses with strong interleukin (IL)-2 cytokine expression. Median T cell responses were 50% higher in donors who had experienced a symptomatic infection, indicating that the severity of primary infection establishes a 'set point' for cellular immunity. T cell responses to spike and nucleoprotein/membrane proteins were correlated with peak antibody levels. Furthermore, higher levels of nucleoprotein-specific T cells were associated with preservation of nucleoprotein-specific antibody level although no such correlation was observed in relation to spike-specific responses. In conclusion, our data are reassuring that functional SARS-CoV-2-specific T cell responses are retained at 6 months following infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / SARS-CoV-2 / COVID-19 / Immunity, Cellular / Antigens, Viral Subject: CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / SARS-CoV-2 / COVID-19 / Immunity, Cellular / Antigens, Viral Language: English Journal: Nat Immunol Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / SARS-CoV-2 / COVID-19 / Immunity, Cellular / Antigens, Viral Subject: CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / SARS-CoV-2 / COVID-19 / Immunity, Cellular / Antigens, Viral Language: English Journal: Nat Immunol Year: 2021
...